B&L unveils its latest offerings to Europe


Bausch & Lomb has announced the launch of three new products onto the European market.

Bausch & Lomb has announced the launch of three new products onto the European market, two of which represent the firm's investment in microincision cataract surgery (MICS), whilst the third presents a further enhancement to its Zyoptix refractive surgery portfolio.

The Stellaris system accommodates both bimanual and coaxial MICS techniques, providing a choice in fluidic control with either the Advance Flow System or Advance Vacuum System, maintaining anterior chamber stability and helping to provide surge-free phaco surgery. Meanwhile, enhanced energy phaco delivery with optimized power modulations adds to the integral safety and efficiency of the system. CE marking is pending and expected during the second quarter of 2007.

The Akreos MI-60 lens completes Bausch & Lomb's Millennium MICS platform. The IOL can be implanted through a 1.8 mm incision using a wound-assisted injection technique where the injection cartridge is prevented from entering the anterior chamber. According to B&L, corneal stress is kept to a minimum using this linear technique, because the incision diameter equals the internal diameter of the cartridge. The lens is made from hydrophilic acrylic and is 30% thinner than the original Akreos AO design.

Finally, the Zyoptix XP Epi Separator, for use with the Zyoptix XP microkeratome handpiece, consists of a proprietary epi head for corneal applanation and a single-use epi separator, which work together to create epithelial flaps in around 12 seconds. It is designed to delivers a precise edge that lifts the epithelium smoothly, leaving a smooth Bowman's layer free of defects and stromal incisions. The device allows the microkeratome to support both LASIK and Epi-LASIK procedures.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.